Premium
Proteomics: Applications and opportunities in preclinical drug development
Author(s) -
Steiner Sandra,
Witzmann Frank A.
Publication year - 2000
Publication title -
electrophoresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 158
eISSN - 1522-2683
pISSN - 0173-0835
DOI - 10.1002/1522-2683(20000601)21:11<2099::aid-elps2099>3.0.co;2-n
Subject(s) - proteomics , drug development , computational biology , genomics , drug discovery , drug , dna sequencing , biology , bioinformatics , genome , pharmacology , dna , genetics , gene
Advances in DNA sequencing and the near‐term availability of whole genome sequences for several pharmaceutically relevant organisms promise to dramatically alter the breadth and scale of high‐throughput proteomic studies. The substantial amount of literature is available in the public domain, demonstrate the potential of proteomics in the preclinical phases of pharmaceutical development. Over the next few years, it is anticipated that functional genomics and proteomics will have major impacts on the clinical phases of drug development. Expected benefits are earlier proof‐of‐concept studies in man and increased efficiency of clinical trials through the availability of biologically relevant markers for drug efficacy and safety.